Regenerative Medicine and Stem Cells Technologies

According to stem cell council public relations and international affairs fourth meeting of knowledge-based companies held with presence of Dr. Sheykh Zeinedin, Deputy for innovation and commercialization and Dr. Hamidieh secretary of council for development of stem cell sciences and technologies.

At the beginning Dr. Hamidieh mentioned approving of biological products regulations at ministry of health and medical education and said, “Specific regulations must also be approved for commercialization of knowledge-based company’s products”. He also told about the preparation of regulations for offering cell therapy services.

Next Dr. Sheikh Zeinedin, Deputy for innovation and commercialization of vice-presidency for science and technology emphasized appropriate creation of knowledge-based companies at the council for development of stem cell sciences and technologies and said, “The law for supporting knowledge-based companies must appropriately execute. The distance between universities and knowledge-based companies must decrease. Also financial support will be given through innovation and prosperity funds.”

He added, “One of the important activities in this field is making strategic demands so that appropriate investments would be given by supporting organizations for commercialization of products.”

Next Dr. Kabir Salmani CEO of Ideal Gene and Cell Company explained complications and obstacles in regulations for registration of knowledge-based companies and emphasized financial support for knowledge-based company’s products.

Dr. Zeinali CEO of Kosar Biology Technology Company emphasized holding of exclusive fairs for exhibiting products of knowledge-based companies and stated, “Given that knowledge-based companies need R&D departments, necessary support must be provided in this regard.”

Dr. Aghdami presented a report for approving regulations of biological products at food and drug deputy of ministry of health. He stated, “Final draft preparation for regulations of cell therapy service offerings is ongoing and all necessary standards have been considered in this regard”

Next Dr. Nikougoftar, Deputy for commercialization and market of the council commented about the difficulties in repayment of loans for knowledge-based companies. She emphasized, “Due to the late efficiency of some products of these companies, appropriate support must be considered in this regard.”

Next Dr. Nozad, CEO of “ARAS research and development and application of stem cells” company emphasized the need to resolve newly formed knowledge-based companies.

Alexander Seifalian, Professor of Nanotechnology & Regenerative Medicine at UCL which his current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer expressed his opinions as follows, “by teamwork we were able to transplant first artificial trachea in human. For stem cell tracking in clinical activities we use quantum dots which will be eaten by cells thus they are useful for capturing videos from inside cells.”

At the end Dr. Amirkhani pointed out holding of the first international congress of stem cells and regenerative medicine and stated,” owner of industries and big pharmaceutical companies must be invited to these congress”. He also told about assessing of top products and researches of big knowledge-based companies at this congress.